Search
Eli Lilly Intends to Introduce Its Experimental Weight-Loss Drug, Orforpligron, in the Indian Market
5 day ago /
Read about 0 minute
Author：小编
According to reports, pharmaceutical behemoth Eli Lilly has decided to discontinue a study on an experimental medication designed to prevent excessive muscle deterioration in obese individuals, attributing the decision to strategic business factors. Moreover, Eli Lilly is set to roll out its experimental weight-loss drug, orforpligron, in India. The drug has demonstrated promising results in clinical trials, outperforming Novo Nordisk's Rybelsus in terms of reducing both blood sugar levels and body weight among patients with type 2 diabetes. This initiative underscores Eli Lilly's strategic approach to capitalize on the escalating demand for weight-loss remedies in highly populated regions.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
